Form 4 Filing for J. Erik Fyrwald

This filing details a Form 4 transaction by J. Erik Fyrwald, a director at Eli Lilly & Co. On April 20, 2026, Mr. Fyrwald acquired 10.78 shares of Eli Lilly's common stock at a price of $919.90 per share. This acquisition, coded as 'A' for acquisition, brings his total post-transaction shares to 75,269.556. Notably, footnote F1 indicates that these shares were acquired in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in stock units, to be converted to shares upon Mr. Fyrwald's separation from service. The transaction was reported on April 21, 2026.